REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Monoclonal Antibody Or Fragment Thereof (i.e., Produced By Any Cloning Technology) > Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Etc.); Or Binds Serum Protein, Plasma Protein (e.g., Tpa, Etc.), Or Fibrin Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Etc.); Or Binds Serum Protein, Plasma Protein (e.g., Tpa, Etc.), Or FibrinBinds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Etc.); Or Binds Serum Protein, Plasma Protein (e.g., Tpa, Etc.), Or Fibrin patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070190058 - Method for treating intraocular neovascular diseases A method is provided for administering to a mammal suffering from, or at risk for, an intraocular neovascular disorder with regular dosing of a therapeutically effective amount of VEGF antagonist, followed by less frequent dosing of a therapeutically effective amount of VEGF antagonist. ... 08/16/07 - 20070190055 - Ccr3 inhibition for ocular angiogenesis and macular degeneration Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis. ... 08/16/07 - 20070190054 - Prevention and treatment of complement-associated disorders The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the prevention and treatment of complement-associated disorders, including complement-associated eye conditions, such as age-related macular degeneration (AMD) and choroidal neovascularization (CNV). ... 08/09/07 - 20070184052 - Soluble tgf-b type iii receptor fusion proteins Soluble fusion proteins of the TGF-β type III receptor and novel methods for their production are disclosed herein for the first time. The fusion proteins of the invention competitively inhibit the binding of members of the TGF-β superfamily to their cell-surface receptors. Also provided are methods for using these fusion ... 08/02/07 - 20070178099 - Suppression of tnfalpha and il-12 in therapy Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed are compositions comprising a TNF antagonist and an IL-12 antagonist. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation. ... 08/02/07 - 20070178098 - Interleukin-6 antagonists The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists of the invention. ... 08/02/07 - 20070178097 - Interleukin-10 antibodies The methods and compositions provided herein relate generally to IL-10 specific antibodies and uses thereof. More specifically, compositions of humanized IL-10 specific antibodies and methods to use such antibodies in modulating the biological activity of IL-10, particularly in autoimmune disorders and pathogen-mediated immunopathology. ... 08/02/07 - 20070178096 - Antibodies to cytokine receptor zalpha11 Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can ... 08/02/07 - 20070178095 - Anti-myostatin antibodies A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope fall within the scope of the invention and may be murine, chimeric, or humanized antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are ... 07/26/07 - 20070172481 - Gdf3 propeptides and related methods In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with ... 07/26/07 - 20070172480 - Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use The invention relates to Glycoprotein VI (GPVI), its isolation, purfication, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases, The ... 07/26/07 - 20070172479 - Protein formulations with reduced viscosity and uses thereof Protein formulations and methods for reducing the viscosity of a protein formulation are provided. The method for reducing the viscosity of a protein formulation comprises adding a viscosity reducing agent, such as calcium chloride or magnesium chloride to the protein formulation. ... 07/19/07 - 20070166310 - Prostatic growth factor The present invention relates to human PGF polypeptides and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques, and antibodies and antagonist/inhibitors against such polypeptides. Also provided are methods of using such polypeptides therapeutically for treating prostate cancer, to promote tissue regeneration ... 07/12/07 - 20070160613 - Monoclonal antibodies to hepatocyte growth factor The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient. ... 07/12/07 - 20070160612 - Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of ... 07/12/07 - 20070160611 - Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. ... 07/12/07 - 20070160610 - Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. ... 07/12/07 - 20070160609 - Interferon antagonists useful for the treatment of interferon related diseases The present invention relates to a process for ameliorating or preventing diseases that are caused, in part, by an increased level of, and/or an abnormal responsivity to, interferon. Specifically, the invention provides compositions and methods for preventing and treating subjects suffering from, or at risk for, such diseases. Such methods ... 07/12/07 - 20070160608 - Treatment with anti-vegf antibodies This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. ... 07/12/07 - 20070160607 - Humanized monoclonal antibodies that protect against shiga toxin induced disease The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment ... 07/12/07 - 20070160606 - Treating renal cell carcinoma with an anti-tnf human antibody or fragment The present invention relates to at least one novel anti-TNF antibody, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices, including the treatment of renal cell carcinoma. ... 07/12/07 - 20070160605 - Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody The invention features methods and compositions for preventing or treating post-surgical pain by administering an anti-NGF antagonist antibody. ... 07/05/07 - 20070154481 - Antibody molecules having specificity for human il-6 The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. ... 07/05/07 - 20070154480 - Humanized antibodies that recognize beta amyloid peptide The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies. ... 07/05/07 - 20070154478 - Therapeutic composition Use of an inhibitor of an hsp 90 protein for the manufacture of a medicament for the treatment or prophylaxis of a condition involving raised levels of TNFα and/or IL-6. ... 06/28/07 - 20070148172 - Method for the treatment of inflammatory bowel disease The present invention provides a method for the treatment and/or prophylaxis of inflammatory bowel disease (IBD) comprising administering a therapeutically effective amount of an inhibitor of CSF-1 activity. ... 06/21/07 - 20070141058 - Method of correcting immunopathological reactions and a medicament The principle of the present invention is the use of an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to cytokines implicated in the course of inflammation, including autoimmune inflammation, the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to ... 06/21/07 - 20070141057 - Anti-tnf antibodies and peptides of human tumor necrosis factor Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of ... 06/21/07 - 20070141056 - Growth factor homolog zvegf3 Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO: 2 or residues 235-345 of SEQ ID NO: 2. Multimers ... 06/21/07 - 20070141055 - Methods and compositions for protein-hydroxy apatite complexes and their application in testing and modulating immunological system including a novel in vitro test for the detection of antibodies against calcium binding protein-hydroxy apatite complexes The invention relates to methods and compositions for the manufacture and use of novel hydroxy apatite (HA)-calcium binding protein (CaBP) complexes (CaBP-HA complex) that are useful as antigen preparations for immunological assays for the diagnosis, prognosis, and monitoring of mammalian diseases. The CaBP-HA complexes may be manufactured using synthetic HA ... 06/14/07 - 20070134246 - Antibodies to tgf-beta The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments ... 06/14/07 - 20070134245 - Rankl antibody-pth/pthrp chimeric molecules Chimeric molecules comprising receptor activator of NF-κB ligand (RANKL) antibodies and parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) peptides are described. Compositions and methods for the treatment of bone diseases are also described. ... 06/14/07 - 20070134244 - Combination treatment for pathologic ocular angiogenesis The present invention provides a combination therapy for the treatment of pathologic ocular disorders, such as age-related macular degeneration and choroidal neovascularization. The combination therapy of the invention includes administration of anecortave acetate and bevacizumab or ranibizumab. ... 06/14/07 - 20070134243 - Antibody drug conjugates and methods where one or more 1,8 bis-naphthalimide drug moieties (D) having Formulas IIa and IIb are covalently linked by a linker (L) to an antibody (Ab). The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula I ADC for treatment of hyperproliferative disorders and other disorders. The ... 06/14/07 - 20070134242 - Mesothelioma therapeutic agent The present invention provides a mesothelioma therapeutic agent containing an interleukin-6 (IL-6) antagonist such as antibody to IL-6 receptor (IL-6R), and a mesothelioma cell growth inhibitor containing an IL-6 antagonist such as antibody to IL-6R. ... 06/07/07 - 20070128198 - Compositions comprising antibodies to human fgl2 Methods for mediating immune coagulation using novel antibodies and compounds are described. A protein Fgl2 having direct prothrombinase activity has been identified. Inhibitors of Fgl2 are useful in preventing and treating diseases which require a reduction in immune coagulation including bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, ... 06/07/07 - 20070128197 - Immunointeractive molecules The present invention relates generally to immunointeractive molecules and more particularly antibodies which bind to vascular endothelial growth factor-B (VEGF-B) or its functional or structural equivalent and inhibit the biological activity of VEGF-B. In particular, the present invention relates to deimmunized such as humanized or human antibodies that bind to ... 06/07/07 - 20070128196 - Methods and compositions for inhibiting angiogenesis Methods for inhibiting angiogenesis in endothelial cells and selectively inducing apoptosis in endothelial cells via compounds which binds annexin II are provided. These compounds and methods for using these compounds are useful in the treatment of diseases or disorders characterized by unwanted angiogenesis. Also provided are pharmaceutical compositions containing a ... 06/07/07 - 20070128195 - Mammalian cytokines; related reagents and methods Nucleic acids encoding mammalian, e.g., primate, IL-1ζ, purified IL-1ζ polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided. ... 06/07/07 - 20070128194 - Preparation of monoclonal antibody to n-myc downstream regulated gene 2 and determination of ndrg2 using protein chip The present invention relates to a monoclonal antibody specific for N-myc downstream regulated gene 2 (NDRG 2) protein, a cell line producing the monoclonal antibody, a method for measuring a quantity and quality of NDRG 2 protein, and a protein chip using the same. In the present invention, NDRG 2, ... 06/07/07 - 20070128193 - Glp-1 agonists, compositions, methods and uses The present invention relates to at least one novel human GLP-1 mimetibody or agonist, or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or agonist, or specified portion or variant, GLP-1 mimetibody or agonist, or specified portion or variants, vectors, host cells, transgenic ... 06/07/07 - 20070128192 - Human antibody molecules for il-13 Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma. ... 06/07/07 - 20070128191 - Polyclonal antibodies, preparation method thereof and use of same Antibodies that specifically bind to amyloid beta peptide Aβ40 or Aβ42, obtainable by immunization of a mammal with a polypeptide conjugated to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, and 4, and method for preparing the antibodies. Preferably, ... 05/31/07 - 20070122413 - Il-21 antagonists Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and ... 05/31/07 - 20070122412 - Eg-vegf nucleic acids and polypeptides and methods of use The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which ... 05/31/07 - 20070122411 - Solid forms of anti-egfr antibodies The invention relates to solid forms of antibodies against the EGF receptor, in particular precipitates and crystals of monoclonal antibodies against the EGF receptor, particularly preferably of Mab C225 (cetuximab) and Mab h425 (EMD 72000), which result in biologically active antibody protein through dissolution or suspension in aqueous medium, obtainable ... 05/24/07 - 20070116704 - Method for the production of an immunostimulating mucin (muc1) The present invention relates to a method for producing or identifying a MUC1 molecule which is able to generate an immune response in humans. The invention also relates to a method for producing or identifying a cell, cell lines or cell lysates containing a MUC1 molecule that is able to ... 05/17/07 - 20070110749 - Centrosome proteins and uses thereof The invention includes nucleic acids and polypeptides that play important roles in centrosomes and cellular functions involving centrosomes. In addition, the invention encompasses antibodies, ribozymes, antisense nucleic acids, RNAis, and siRNAs that can be used to modulate the function of the nucleic acids and polypeptides of the invention. Such modulation ... 05/17/07 - 20070110748 - Fibronectin binding protein compositions and methods of use Disclosed are antibodies that block the binding of fibronectin protein to fibronectin. Also disclosed are site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB genes of Staphylococcus aureus, the fnbA and fnbB genes of Streptococcus dysgalactiae, and the sfb gene of Streptococcus pyogenes, and nucleic acid segments ... 05/17/07 - 20070110747 - Binding agents Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. ... 05/10/07 - 20070104713 - Nogo receptor homologs The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes ... 05/10/07 - 20070104712 - Treatment of inflammatory bowel disease with ifn-gamma inhibitors The invention concerns a method for the prevention or treatment of inflammatory bowel disease by administering an interferon-γ inhibitor. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method. ... 05/10/07 - 20070104711 - Use of certain drugs for treating nerve root injury The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. ... 05/10/07 - 20070104710 - Ligand that has binding specificity for il-4 and/or il-13 The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity. ... 05/03/07 - 20070098727 - Use of cytokine expression to predict skin inflammation; methods of treatment Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23. ... 05/03/07 - 20070098726 - Methods of making and using antibodies directed to parathyroid hormone The present invention relates to methods of generating anti-PTH antibodies and antibodies generated by the methods of the invention. The anti-PTH antibodies generated by the methods of the invention specifically bind to an epitope on a whole PTH (1-84) which includes one or more N-terminal amino acid residues of the ... 05/03/07 - 20070098725 - Peptide-based immunization therapy for treatment of atherosclerosis The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. ... 05/03/07 - 20070098724 - Methods of treatment using vascular occlusion in combination with one or more therapies The present invention relates generally to methods and compositions for treating a disease or condition by administering a first therapeutic protocol comprising targeting and delivering solid-phase platelet-dependent vascular occlusion agents, and administering at least one second therapeutic composition or method. ... 05/03/07 - 20070098723 - Peptide-based passive immunization therapy for treatment of atherosclerosis The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method ... 05/03/07 - 20070098722 - Medicament comprising inhibitors of long pentraxin ptx3 The use of inhibitors of long pentraxin PTX3 for the preparation of a medicament for the prevention and treatment of autoimmune diseases and of degenerative diseases of bone and cartilage is described. ... 05/03/07 - 20070098721 - Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof The invention relates to neuromodulatory oligomers of the amyloid-β(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers as diagnostic and therapeutics agents, for the generation of oligomer-specific antibodies and for the discovery ... 04/26/07 - 20070092518 - Anti-tnfalpha antibodies and methods of use Novel TNFα antibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to treat TNFα-related diseases are also disclosed. ... 04/26/07 - 20070092517 - Truncated memapsin 2 compositions and treatments The present invention provides novel methods of reducing memapsin 2 β-secretase activity in a subject, decreasing levels of β-amyloid peptide in the brain of a subject, treating Alzheimer's disease and/or reducing the size and/or number of β-amyloid plaques in the brain of a subject. The methods may include the step ... 04/19/07 - 20070087003 - Methods of treating a blood pathology using anti-tnf antibodies and fragments thereof Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of ... 04/19/07 - 20070087002 - Anticholesterol immunoglobulin to treat lipid raft diseases Immunoreactive compositions and methods for immunizing animal, including, humans, cows, and fowl, against cholesterol and cholesterol derivatives, including cholesterol oxides, and their use in methods for reducing and preventing lipid raft-based diseases, including, but not limited to HIV-1, SARS, prion formation in Creutzfeldt-Jakob disease, and neutralizing oxidized modified lipoproteins, specifically, ... 04/19/07 - 20070087001 - Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PlGF ligands, alone or ... 04/19/07 - 20070087000 - Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of ... 04/19/07 - 20070086999 - Compositions and methods including a recombinant human mab that promotes cns remyelination Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise ... 04/12/07 - 20070081996 - Method of treating depression using a tnfalpha antibody The invention describes methods of treating depression comprising administering a TNFα antibody, such as a human TNFα antibody. ... 04/12/07 - 20070081995 - Methods and compositions for targeting ifnar2 Anti-IFNAR2 monoclonal antibodies, and methods for using the antibodies, are provided. ... 04/05/07 - 20070077249 - Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the ... 04/05/07 - 20070077248 - Tumour necrosis factor binding ligands The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of ... 03/29/07 - 20070071749 - Treatment with anti-vegf antibodies This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. ... 03/29/07 - 20070071748 - Treatment with anti-vegf antibodies This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. ... 03/29/07 - 20070071747 - Use of tnfalpha inhibitor for treatment of erosive polyarthritis The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis. ... 03/22/07 - 20070065442 - Compositions and methods for treating hyperimmune response in the eye The present invention comprises and utilizes methods and compositions for treating hyperimmune reactions in the eye. Compositions comprising antibodies to gamma interferon alone and in combination with other drugs are described. Also disclosed in the invention are methods of applying a composition comprising interferon gamma antibodies topically to the eye ... 03/22/07 - 20070065441 - Human pf4a receptors, nucleic acid encoding and antibodies binding thereto cDNAs encoding a class of receptors, including the IL-8 receptor, have been identified in human tissue. Recombinantly produced PF4ARs are used in the preparation and purification of antibodies capable of binding to the receptors, and in diagnostic assays. The antibodies are advantageously used in the prevention and treatment of inflammatory ... 03/22/07 - 20070065440 - Antibody compositions and methods Provided are concentrated preparations comprising single immunoglobulin variable domain polypeptides that bind target antigen with high affinity and are soluble at high concentration, without aggregation or precipitation, providing, for example, for increased storage stability and the ability to administer higher therapeutic doses. ... 03/22/07 - 20070065439 - Antibodies against interleukin-1 beta Antibodies directed to the antigen IL-1β and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen IL-1β. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the ... 03/15/07 - 20070059313 - Homogeneous preparations of il-28 and il-29 Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity ... 03/15/07 - 20070059312 - Anti-vegf antibodies Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. ... 03/15/07 - 20070059311 - Regulation of the hedgehog signaling pathway and uses thereof The present invention provides molecular mechanism leading to the development of cancers associated with hedgehog signaling pathway. These cancers may develop as a result of a chronic bacterial or a chronic viral infection. The present invention provides methods for early detection of such cancers. Additionally, it also provides measures that ... 03/15/07 - 20070059310 - Therapeutic combination compositions and methods of using same The present invention encompasses a therapeutic combination composition of a β-glucan EGF receptor antagonist. This therapeutic combination composition is useful for the treatment of diseases including proliferative disorders and immune dysfunction. ... 03/15/07 - 20070059309 - Anti-interferon-alpha antibodies The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders ... 03/08/07 - 20070053909 - Method of treating fibrosis Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3 antagonist in combination with a pharmaceutically acceptable delivery vehicle, wherein the zvegf3 antagonist is an antibody that ... 03/08/07 - 20070053908 - Uses of human zven antagonists The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods of using antagonists to Zven1 and Zven2 to treat inflammation in the intestine. ... 03/08/07 - 20070053907 - Uses of human zven antagonists The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods of using antagonists to Zven1 and Zven2 to treat inflammation in the intestine. ... 03/08/07 - 20070053906 - Liquid formulations of tumor necrosis factor-binding proteins The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent. ... 03/08/07 - 20070053905 - Agent for treating chondroma and chondrosarcoma The present invention relates to a novel agent for treating chondroma and chondrosarcoma containing a substance which inhibits binding of parathyroid hormone related peptide to its receptor for improving the prognosis of chondroma or chondrosarcoma. ... 03/01/07 - 20070048319 - Antibodies that bind both bcma and taci Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane ... 03/01/07 - 20070048318 - Method for treating psoriasis A method for treating psoriasis. An antagonist to IL-17Dβ9 (IL-17D) is administered to treat psoriasis. The antagonist can be an antibody that binds to IL-17Dβ9 or its receptor or a soluble receptor that binds to IL-17Dβ9 or a membrane-spanning protein-5 (MSP-5). ... 03/01/07 - 20070048317 - Method of treating fibroproliferative disorders Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, ... 03/01/07 - 20070048316 - Method of reducing proliferation of cells in a mammal Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, ... 03/01/07 - 20070048315 - Engineered anti-il-23 antibodies Engineered antibodies to human IL-23pl9 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. ... 03/01/07 - 20070048314 - Process for preparing purified drug conjugates The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step. ... 03/01/07 - 20070048313 - Hybridoma cell lines and monoclonal antibodies recognizing prox1 Monoclonal antibodies to Prox1 of vertebrates (pfam05044.5; NM_002763.3) and two continuous cell lines for their production are disclosed. These antibodies are particularly useful in immunoassays to detect the presence of Prox1 protein in vertebrate tissues and cells. ... 03/01/07 - 20070048312 - Anti-addl antibodies and uses thereof The invention herein comprises antibodies that bind to amyloid beta-derived diffusible ligands (ADDLs). ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. ... 03/01/07 - 20070048311 - Anti-interferon-alpha antibodies The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders ... 02/22/07 - 20070041976 - Methods and compositions relating to anti-interleukin-4 receptor antibodies Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that ... 02/22/07 - 20070041975 - Homogeneous preparations of il-28 and il-29 Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity ... 02/22/07 - 20070041974 - Cytokine zalpha11 ligand antibodies Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller ... 02/22/07 - 20070041973 - Compositions and methods for treating, preventing and/or reversing type-1 diabetes The present invention relates generally compounds, compositions, combinations, kits, and methods for treatment; prevention, suppression, and/or delaying the onset of type 1 diabetes, or reversal of type 1 diabetes. ... 02/22/07 - 20070041972 - Antibodies and fusion proteins that include engineered constant regions Antibodies and/or fusion proteins contain a region that includes an IgG2-derived portion IgG4-derived portion. ... 02/15/07 - 20070036792 - Antibodies that specifically bind to reg iv The present invention relates to antibodies and related molecules that specifically bind to Reg IV. Such antibodies have uses, for example, in the prevention and treatment of gastrointestinal tract cancers, inflammatory bowel disorders, and diabetes. The invention also relates to nucleic acid molecules encoding anti-Reg IV antibodies, vectors and host ... 02/15/07 - 20070036791 - Interleukin-17 receptor homologue Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.” ... 02/15/07 - 20070036790 - Treatment with anti-vegf antibodies This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. ... 02/15/07 - 20070036789 - Neutralizable epitope of hgf and neutralizing antibody binding to the same The neutralizing antibody against HGF binding to the inventive neutralizable epitope of HGF is capable of neutralizing HGF as a single agent, and can be effectively used for preventing and treating intractable diseases and cancers that are caused by binding of HGF to its receptor Met. ... 02/15/07 - 20070036788 - Use of a compound for reducing the biological effectiveness of il-6 Use of a compound comprising at least a structural entity which binds or is an antagonist for interleukin-6 (IL-6) and/or the IL-6 receptor or parts of it, preferably human IL-6 which compound depletes IL-6 from a solution or blocks at least one or more IL-6 functions on cell surfaces or ... 02/15/07 - 20070036787 - Insulin-induced gene as therapeutic target in diabetes The present invention relates to the use of a modulator of the expression or activity of the E2IG4 gene for the treatment of diabetes or its complications, obesity or insulin resistance, to a method of screening compounds useful in the treatment of these pathological conditions, and to a method for ... 02/08/07 - 20070031414 - Dr5 antibodies and uses thereof The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer. ... 02/08/07 - 20070031413 - Treatment with anti-vegf antibodies This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. ... 02/08/07 - 20070031412 - Direct and indirect effector cell protease receptor-1 (epr-1) inhibitors as antiplatelet agents Direct and indirect effector cell protease receptor-1 (EPR-1) inhibitors may be used for the treatment of conditions associated with platelet aggregation as antiplatelet agents. ... 02/08/07 - 20070031411 - Vaccine comprising a tick cement protein The invention relates to the use of tick cement proteins in the production of vaccines for protecting animals against the bite of blood-sucking ectoparasites and against the transmission of viruses, bacteria and other pathogens by such ectoparasites. When used as vaccine components, the tick cement proteins of the invention confer ... 02/08/07 - 20070031410 - Pop2: nfkb - inhibiting polypeptides, nucleic acids and methods of use This invention provides a novel pyrin-only protein (POP2), polypeptides, nucleic acids encoding them and methods for making and using them. The polypeptides of this invention have nuclear factor-κB (NF-κB) modulating activity. NF-κB is pivotal for transactivation of cell-cycle regulatory, cytokine and adhesion molecule genes and is dysregulated in many cancers, ... 02/08/07 - 20070031409 - Recombinant dna-molecule complex for the expression of anti-human-interferon-gamma chimeric antibodies or antibody fragments A method for producing biologically active Fv antibody fragments that have a neutralizing effect on the anti-viral activity of human interferon-gamma (IFN-Γ) by inserting an isolated nucleic acid, having nucleotide sequences that encode the VH and VL domains of the D9D10 monoclonal antibody and a nucleotide sequence that encodes a ... 02/01/07 - 20070025994 - Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to interleukin 5 (IL-5), which is preferably human IL-5. The invention also relates to human anti-IL-5 antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and ... 02/01/07 - 20070025993 - Tek antagonists The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization. ... 02/01/07 - 20070025992 - Monoclonal antibody against platelet membrane glycoprotein vi The present invention provides a human antibody or an active-fragment thereof that specifically binds to human platelet membrane glycoprotein VI and does not induce a human platelet aggregation independently; a cell that produces the antibody or its active-fragment; a pharmaceutical composition that comprises the antibody or its active-fragment as an ... 02/01/07 - 20070025991 - Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation Methods for treating intestinal inflammation or ghrelin-mediated inflammation by inhibiting the activity of ghrelin or its receptor are described. Also described are methods for identifying ghrelin antagonists and ghrelin receptor antagonists. ... 01/25/07 - 20070020268 - Treatment of inflammatory bowel disease with ifn-gamma inhibitors The invention concerns a method for the prevention or treatment of inflammatory bowel disease by administering an interferon-γ inhibitor. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method. ... 01/25/07 - 20070020267 - Anti-vegf antibodies Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in ... 01/25/07 - 20070020266 - Gpr54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases The invention provides an agonist or antagonist of the GPR54 receptor for its use for treating a gonadotropin related disorder, a ligand of the GPR54 receptor for its use for diagnosing a subject's gonadotropin abnormality; a method for screening a compound that affect the gonadotropic axis comprising the step of ... 01/18/07 - 20070014800 - Cytokine zalpha11 ligand antibodies Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller ... 01/18/07 - 20070014799 - Antibody and use of the same The present invention provides a novel antibody useful in developing therapeutic, preventive and diagnostic agents for diseases associated with human ZAQL-2, a method of quantifying ZAQL-2 by using the antibody, etc. More particularly, the present invention provides an antibody reacting specifically with human ZAQL-2 or its derivatives, a method of ... 01/11/07 - 20070009527 - Method for cloning of variable domain sequences The present invention relates to a method for cloning immunoglobulin variable domain sequences derived from immunoglobulins, and a repertory library of immunoglobulin variable domain sequences made according to the method. ... 01/11/07 - 20070009526 - Anti-il-23 antibodies, compositions, methods and uses An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. ... 01/11/07 - 20070009525 - Human endokine alpha and methods of use The present invention concerns a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are ... 01/11/07 - 20070009524 - Methods of treating inflammation associated with viral infection with anti-tnf antibodies Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of ... 01/04/07 - 20070003550 - P53 vaccines for the treatment of cancers The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is ... 01/04/07 - 20070003549 - Ligands that have binding specificity for vegf and/or egfr and methods of use therefor Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described. ... 01/04/07 - 20070003548 - Anti-tnf antibodies, compositions, methods and uses The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. ... 12/28/06 - 20060292148 - Antihuman tnf-alpha antibody activity lowering inhibitor The present invention provides an antihuman TNF-α antibody activity lowering inhibitor comprising a protein source(s) and/or carbohydrate source(s), in the treatment of inflammatory bowel syndrome with repeated administration of anti-TNF-α antibody; and a kit preparation wherein a freeze-dried antihuman TNF-α antibody and the activity lowering inhibitor in the above repeated ... 12/28/06 - 20060292147 - Blood mmp-3 level-lowering agent comprising il-6 antagonist as active ingredient A blood matrix metalloprotease-3 (MMP-3) level-lowering agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient. ... 12/28/06 - 20060292146 - Isolated ptpmt1 protein which mediates insulin production and uses thereof The invention identifies a novel protein tyrosine phosphatase, PTPMT1. The complete nucleic acid and amino acid sequence encoding PTPMT1 is provided. Methods are provided for preventing and/or treating type II diabetes by regulating PTPMT1 levels, which in turn regulates insulin levels. ... 12/28/06 - 20060292145 - Human antihuman interleukin-18 antibody, fragment thereof and method for using same A human-derived human anti-human IL-18 antibody of the present invention is an antibody against human IL-18, the antibody including: an H-chain complementarity determining region consisting of (a) a polypeptide consisting of amino-acid sequences represented by SEQ ID NOS: 4 to 6, or (b) a polypeptide which is a mutant of ... 12/21/06 - 20060286108 - Topical compositions for the treatment of chronic wounds Methods for treating chronic wounds in a human are described by topically administering a dermatological composition comprising a TNF antagonist, a TACE inhibitor, a neutrophil antagonist, or a combination of a TNF antagonist and/or TACE inhibitor and a neutrophil antagonist. The TNF antagonist administered includes alefacept, efalizumab, etanercept, adalimumab, and ... 12/21/06 - 20060286107 - Parathyroid hormone antibodies and related methods Methods of preparing antibodies that recognize and bind three-dimensional epitopes of antigens are disclosed. The methods are particularly useful for preparing antibodies that bind the bioactive, three-dimensional amino terminus of parathyroid hormone. The antibodies so produced are used in diagnostic and therapeutic applications. ... 12/21/06 - 20060286106 - Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents A diagnostic method of monitoring anti-inflammatory and/or antioxidant actions of therapeutic agents comprises determining the level of at least one systemic marker indicative of inflammation or oxidation in a bodily sample taken from a subject at base line or following administration of the therapeutic agent. The marker includes at least ... 12/21/06 - 20060286105 - Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency The disclosure provides methods for treating, preventing, and reducing risk of occurrence of renal insufficiency in mammals. The disclosed methods include administering to a subject susceptible to, or afflicted with, renal disorder therapeutically effective amounts of a TGF-β antagonist and a renin-angiotensin-aldosterone system (RAAS) antagonist so as to maintain desirable ... 12/14/06 - 20060280744 - Methods for treating demyelination disorders This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an animal model that exhibits hypomyelination. The compositions and methods embodied in ... 12/14/06 - 20060280743 - Humanized antibodies that recognize beta amyloid peptide The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies. ... 12/14/06 - 20060280742 - Methods of inhibiting tnf-alpha in patients with crohn's disease Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of ... 12/07/06 - 20060275298 - Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases Oromucosal administration of antagonists of cytokines associated with stimulation or enhancement of T helper 1 cell responses, preferably for example a Type 1-interferon antibody, is disclosed for inhibition or prevention of auto immune diseases. ... 12/07/06 - 20060275297 - Mammalian cx3c chemokine antibodies Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided. ... 12/07/06 - 20060275296 - Il-31 monoclonal antibodies and methods of use The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by ... 12/07/06 - 20060275295 - Activity of thap-family chemokine-binding domains Among the methods and compositions described herein are methods of ameliorating one or more symptoms associated with a chemokine-mediated or influenced condition by providing to a subject an agent that includes a polypeptide comprising a chemokine binding domain of a THAP-family polypeptide. ... 12/07/06 - 20060275294 - Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease an This invention relates to a method for prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a ... 12/07/06 - 20060275293 - Splice variant of the human pituitary growth hormone This invention relates to a novel protein, termed INSP101, herein identified as a novel splice variant of human pituitary growth hormone and to the use of this protein and nucleic acid sequences from the encoding genes in the diagnosis, prevention, and treatment of disease. ... 11/30/06 - 20060269551 - Method for treating inflammation A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, ... 11/30/06 - 20060269550 - Anti-ghrelin fab antibodies Monoclonal antibodies and antigen-binding portions thereof that preferentially bind acetylated human ghrelin with respect to unacylated human ghrelin are disclosed. These molecules have high affinity for acylated human ghrelin, a slow off rate for acylated human ghrelin dissociation, and neutralize an acylated human ghrelin activity. These antibodies or antigen-binding portions ... 11/30/06 - 20060269549 - Tnf-alpha binding molecules The present invention relates to TNF-α binding molecules and nucleic acid sequences encoding TNF-α binding molecules. In particular, the present invention relates to TNF-α binding molecules with a high binding affinity, a high association rate, a low dissociation rate with regard to human TNF-α and that are capable of neutralizing ... 11/23/06 - 20060263364 - Mammalian chemokines; related reagents Novel CC chemokines from human, reagents related thereto including purified proteins, specific antibodies and nucleic acids encoding these chemokines are provided. Also provided are methods of making and using said reagents and diagnostic kits. ... 11/23/06 - 20060263363 - Anti-interferon gamma antibodies and methods of use thereof The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hIFNγ), thereby modulating the interaction between IFNγ and its receptor, IFNγ-R, and/or modulating the biological activities of IFN-γ. The invention also relates to the use of such anti-IFNγ antibodies in the prevention or treatment ... 11/23/06 - 20060263362 - Cancer metastasis inhibitor An object of the present invention is to provide a cancer metastasis inhibitor or, more particularly, a useful pharmaceutical composition for treating of bone metastasis and liver metastasis. In accordance with the invention, a cancer metastasis inhibitor comprising a substance inhibiting the activity of IGF (insulin-like growth factor)-I and IGF-II ... 11/23/06 - 20060263361 - Pan-kir2dl nk -receptor antibodies and their use in diagnostik and therapy The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and ... 11/23/06 - 20060263360 - Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives A composition and method utilizes a substantially purified composition including an adhesive and a polypeptide containing amino acid sequence LKKTET or a conservative variant thereof. ... 11/23/06 - 20060263359 - Diagnostics and therapeutics for diseases associated with dopamine receptor d4 (drd4) The invention provides a human DRD4 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, hematological disorders, neurological ... 11/16/06 - 20060257408 - Method for influencing kinase pathways with il-22 Interleukin-22 interacts with its receptor, referred to as IL-22R, and instigates a series of reactions, leading to activation of various molecules, such as JAK-1, Tyk2, and others. One can identify molecules which mediate this interaction by measuring the activity of one or more of the molecules in the pathway, to ... 11/16/06 - 20060257407 - Anti-il-6 antibodies, compositions, methods and uses An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. ... 11/16/06 - 20060257406 - Ligand The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity for a target ligand and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity for a receptor of the target ligand. ... 11/16/06 - 20060257405 - Diagnostics and therapeutics for diseases associated with aryl hydrocarbon receptor (ahr) The invention provides a human AHR which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, respiratory diseases, urological diseases and gastroenterological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders ... 11/09/06 - 20060251660 - Antibodies to human il-1beta An IL-1β binding molecule, in particular an antibody to human IL-1β, especially a human antibody to human IL-1β is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteroporosis ... 11/09/06 - 20060251659 - Method for screening molecules that restore nod1 activity in cells containing an nod2 mutation that reduces or eliminates nod1 activity A method for identifying a molecule that restores Nod1 activity in cells which contain a Nod2 mutation that reduces or eliminates Nod1 activity. Nod2/CARD15 is the first characterized susceptibility gene in Crohn's disease. The Nod2 1007fs (Nod2fs) frameshift mutation is the most prevalent in Crohn's disease patients. Muramyl dipeptide (MDP) ... 11/09/06 - 20060251658 - Antibodies to tgf-beta The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments ... 11/09/06 - 20060251657 - Treatment kit which assists with antibiotic therapy for intracellular infectious diseases The present invention describes the use of immunomodulators to support the usual treatment against infectious diseases caused by facultative intracellular organisms. Starting from an analysis of the immune response installed in this type of infection, particularly the infection caused by Tuberculosis, a treatment kit is used that associates a soluble ... 11/09/06 - 20060251656 - New pharmaceutical compositions based on anticholinergics and anti-tnf antibodies The present invention relates to novel pharmaceutical compositions based on anticholinergies and anti-TNF antibodies, processes for preparing them and their use in the treatment of respiratory diseases. ... 11/09/06 - 20060251655 - Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same It is intended to provide an antibody showing immunoreactivity selectively to ADAMTS-13 and applications of this antibody in epitope analysis or diagnosis of an ADAMTS-13 autoantibody-positive patient. Alternatively, it is intended to provide a process for producing and use of a modified ADAMTS-13 molecule partially deleted aiming at the application ... 11/02/06 - 20060246073 - Anti-tnf antibodies and peptides of human tumor necrosis factor Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of ... 11/02/06 - 20060246072 - Methods of facilitating cell survival using neurotrophin mimetics Methods and compounds for treating neurodegenerative and other disorders. Included is the administering to a subject in need thereof an effective amount of a compound having binding specificity for a p75NTR receptor molecule. Enhanced survival of neural and other cells has been observed. ... 11/02/06 - 20060246071 - Antibodies directed to angiopoietin-2 and uses thereof Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the ... 11/02/06 - 20060246070 - Methods and compositions for treating renal cell carcinoma related pathologies The present invention relates to methods for treating at least one renal cell carcinoma related condition or pathology, including therapeutic compositions, methods and devices, using TNF antagonists. ... 11/02/06 - 20060246069 - Human anti-human mcp-1 antibody and fragment of said antibody A substance effective for treating immunopathy where MCP-1 is involved is provided. scFv having a high affinity to human MCP-1 was obtained using phage antibody technique. Based on information of VH chain and VL chain obtained from said scFv, a human anti-human MCP-1 antibody and a human anti-human MCP-1 antibody ... 10/26/06 - 20060240018 - Artificial antibody polypeptides A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of ... 10/26/06 - 20060240017 - Human anti-tnf antibodies and peptides Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of ... 10/26/06 - 20060240016 - Activity of thap-family chemokine-binding domains Described herein are chemokine-binding domains of THAP-family polypeptides and pharmaceutical compositions which include a polypeptide comprising a chemokine-binding domain of a THAP-family polypeptide. Also disclosed are methods of binding chemokines, inhibiting the activity of chemokines, detecting chemokines, and reducing the symptoms associated with a chemokine mediated or influenced condition by ... 10/26/06 - 20060240015 - Recombinant antibody against human insulin-like growth factor It is demanded that pharmaceutical agents for therapeutic treatment of diseases such as cancer, acromegaly and diabetic complications, of which IGF is involved in the progress of the conditions. The present invention provides a recombinant antibody or an antibody fragment thereof which specifically binds to human insulin-like growth factor-I (hereinafter ... 10/26/06 - 20060240014 - Methods and compounds for the treatment of vascular stenosis This invention features a method of treatment for vascular stenosis or restenosis using a combination of N-phenyl-2-pyrimidine derivatives such as imatinib mesylate and PI3K inhibitors, such as rapamycin. ... 10/26/06 - 20060240013 - Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37) The invention provides a human BG37 which is associated with the disorders of the gastroenterology system, disorders of the peripheral and central nervous system, urology diseases, hematology diseases, cancer diseases, inflammation and cardiovascular diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention ... 10/26/06 - 20060240012 - Human antihuman interleukin-6 antibody and fragment of antibody A substance effective for treating immunopathy where interleukin 6 (IL-6) is involved is provided. A human anti-human IL-6 antibody and a human anti-human IL-6 antibody fragment having a high affinity to human IL-6 were obtained using phage antibody technique. Said antibody and antibody fragment are expected to be useful as ... 10/26/06 - 20060240011 - Use of nf-kappa b inhibitors for the treatment of mastitis The present invention relates to the use of NF-KB (NF-kappa B) inhibitors for the manufacture of a medicament for the treatment of mastitis. ... 10/19/06 - 20060233804 - Igf antagonist peptides Peptides are provided that antagonize the interaction of IGF-1 with its binding proteins, insulin receptor, and IGF receptor. These IGF antagonist peptides are useful in treating disorders involving IGF-1 as a causative agent, such as, for example, various cancers. ... 10/19/06 - 20060233803 - Use of a33 antigens and jam-it The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer. ... 10/19/06 - 20060233802 - Tumour necrosis factor binding ligands The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of ... 10/19/06 - 20060233801 - Compositions and methods for increasing bone mineralization A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules. In particular, compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate ... 10/19/06 - 20060233800 - Biological products There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the ... 10/19/06 - 20060233799 - Use of il-18 inhibitors for treatment and/or prevention of peripheral vascular diseases The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation. ... 10/12/06 - 20060228360 - Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12 The present invention provides a method for enhancing oral tolerance to an antigen associated with an autoimmune disease in a subject having the autoimmune disease comprising orally administering to the subject an antigen associated with the autoimmune disease and administering an inhibitor of interleukin-12 in amounts sufficient to enhance oral ... 10/12/06 - 20060228359 - Antibodies to myeloid progenitor inhibitory factor-1 (mpif-1) There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine β8 (CKβ8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-γ and chemokine β1(CKβ1 or ckb-1)), and a macrophage inhibitory protein-4 ... 10/12/06 - 20060228358 - Antibody molecules having specificity for human il-1 beta The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1β, the uses of the antibody molecule and methods for producing said antibody molecule. ... 10/05/06 - 20060222646 - Anti-tnfalpha antibodies in therapy of asthma The present invention provides for uses of an anti-TNFα antibody or an antigen-binding fragment thereof for the manufacture of a medicament for use in the treatment of asthma or airway inflammation in an individual in need thereof. The present invention also provides for use of an anti-TNFα antibody or an ... 10/05/06 - 20060222645 - Monoclonal antibodies against angptl4 Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided. ... 09/28/06 - 20060216296 - Compositions and methods for promoting or inhibiting angiogenesis Compounds, compositions and methods for promoting or inhibiting angiogenesis, and screening methods for identifying compounds are disclosed. The compounds bind to F1 ATP synthase particularly to the alpha and/or beta subunits of F1 ATP synthase. When bound to these subunits, they can function as angiostatin agonists, antagonists, partial agonists, inverse ... 09/28/06 - 20060216295 - Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy Disclosed herein are methods for the identification of effector molecules useful in the treatment of vulvovaginal atrophy. Methods of treating vulvovaginal atrophy comprising administering the effector molecules are also disclosed. ... 09/28/06 - 20060216294 - Method of modulation Disclosed are methods for modulating neuron activity, and in particular, for modulating motor neuron function and activity, particularly for use in the treatment, prevention, and/or amelioration of symptoms of one or more motor neuron conditions or diseases in a mammal. Also disclosed are compositions comprising one or more agonists or ... 09/28/06 - 20060216293 - Tnfalpha-neutralizing antibodies The invention provides monoclonal antibodies that neutralize TNα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of ... 09/28/06 - 20060216292 - Treatment of neurodegenerative diseases The present invention relates to the uses of FADS2 interacting molecules, especially FADS2 inhibitors, for the preparation of a medicament for the treatment of neurodegenerative diseases, specially Alzheimer's disease. ... 09/21/06 - 20060210566 - Methods of treating anemia by inhibition of vascular endothelial growth factor (vegf) Methods of treating anemic disorders in human subjects comprising administering a VEGF antagonist comprising a fusion polypeptide having an immunoglobulin-like (Ig) domain 2 of the VEGF receptor Flt1 and Ig domain 3 of the VEGF receptor Flk1 or Flt4, and a multimerizing component. Further included are methods of preventing anemia, ... 09/21/06 - 20060210565 - Antagonists of hmg1 for treating inflammatory conditions There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring ... 09/21/06 - 20060210564 - Novel diabody-type bispecific antibody The purpose of the present invention is to provide a diabody-type bispecific antibody, which is characterized by having low immunogenicity and high infiltrating activity into tumor tissues, and by being easily mass-produced at a low cost with use of microorganisms, and by being easily altered in function by means of ... 09/21/06 - 20060210563 - Administration of anti-cytokine f(ab')2 antibody fragments The present invention is directed to a method of treating a cytokine-mediated immune reaction in a patient in need of such treatment by administration of an effective amount of anti-cytokine F(ab′)2 antibody fragments. The antibody fragments are preferably free from albumin and of whole antibodies, as well as substantially free ... 09/21/06 - 20060210562 - Treatment of type 1 diabetes before and after expression of predisposition markers The present invention relates generally to the use of compounds, compositions, combinations, kits, and methods for the effective endocytic presentation of immunosuppressive factors for the down regulation of diabetogenic T cells for the treatment of type I diabetes. ... 09/14/06 - 20060204499 - Tumour necrosis factor binding ligands The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of ... 09/14/06 - 20060204498 - Novel antagonists of cxcr3-binding cxc chemokines Novel antagonists of CXCR3-binding CXC chemokines, and in particular of human CXCL11, can be obtained by generating mutants of such chemokines in which the binding to glycosaminoglycans (GAGs) is impaired due to non-conservative substitutions of amino acids involved in this interaction. Compounds prepared in accordance with the present invention can ... 09/07/06 - 20060198844 - Bone morphogenetic protein-2 in the treatment and diagnosis of cancer The present invention pertains to the use of BMP-2, which is overexpressed in most common cancers, as 1) a target for cancer treatment therapies and 2) a means to diagnose cancer. The therapeutic component of this invention involves administering to a patient a composition that inhibits bone morphogenetic-2 activity. Such ... 09/07/06 - 20060198843 - Treatment with anti-erbb2 antibodies and chemotherapeutic agents The present application describes methods for treating can |